Lithium treatment - moderate dose use study (LiTMUS) for bipolar disorder

Rationale and design

Andrew A. Nierenberg, Louisa G. Sylvia, Andrew C. Leon, Noreen A. Reilly-Harrington, Terence A. Ketter, Joseph R. Calabrese, Michael E. Thase, Charles L. Bowden, Edward S. Friedman, Michael J. Ostacher, Lena Novak, Dan V. Iosifescu

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background Recent data indicate that lithium use for bipolar disorder has declined over the last decade and that lithium largely has been replaced with alternate, commercially promoted medications that may or may not result in better outcomes. Purpose This article describes the rationale and study design of LiTMUS, a multisite, prospective, randomized clinical trial of outpatients with bipolar disorder. LiTMUS seeks to address whether initiating therapy at lower doses of lithium as part of optimized treatment (OPT, guideline-informed, evidence-based, and personalized pharmacotherapy) improves outcomes and decreases the need for other medication changes across 6 months of therapy. Methods LiTMUS will randomize 284 adults with bipolar disorder (Type I or II) across 6 study sites. The co-primary outcomes are overall illness severity on clinical global improvement scale for bipolar disorder and a novel measure, necessary clinical adjustments. This metric provides a composite that reflects both clinical response and tolerability. Other relevant outcomes include full symptomatic recovery, quality of life, suicidal behaviors, and moderators of suicidality. Results As of August 28th, 2009, we have consented 338 patients and randomized 281 for this study. Limitations The potential limitations of the study include an arbitrary definition of 'low, but effective' doses of lithium, lack of a placebo-controlled group, open treatment, and use of a new outcome measure (i.e., necessary clinical adjustments). Conclusion We expect that this study will inform our understanding of the effectiveness of low to moderate doses of lithium therapy for individuals with bipolar disorder.

Original languageEnglish (US)
Pages (from-to)637-648
Number of pages12
JournalClinical Trials
Volume6
Issue number6
DOIs
StatePublished - 2009

Fingerprint

Bipolar Disorder
Lithium
Social Adjustment
Therapeutics
Outpatients
Randomized Controlled Trials
Placebos
Quality of Life
Outcome Assessment (Health Care)
Guidelines
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

Nierenberg, A. A., Sylvia, L. G., Leon, A. C., Reilly-Harrington, N. A., Ketter, T. A., Calabrese, J. R., ... Iosifescu, D. V. (2009). Lithium treatment - moderate dose use study (LiTMUS) for bipolar disorder: Rationale and design. Clinical Trials, 6(6), 637-648. https://doi.org/10.1177/1740774509347399

Lithium treatment - moderate dose use study (LiTMUS) for bipolar disorder : Rationale and design. / Nierenberg, Andrew A.; Sylvia, Louisa G.; Leon, Andrew C.; Reilly-Harrington, Noreen A.; Ketter, Terence A.; Calabrese, Joseph R.; Thase, Michael E.; Bowden, Charles L.; Friedman, Edward S.; Ostacher, Michael J.; Novak, Lena; Iosifescu, Dan V.

In: Clinical Trials, Vol. 6, No. 6, 2009, p. 637-648.

Research output: Contribution to journalArticle

Nierenberg, AA, Sylvia, LG, Leon, AC, Reilly-Harrington, NA, Ketter, TA, Calabrese, JR, Thase, ME, Bowden, CL, Friedman, ES, Ostacher, MJ, Novak, L & Iosifescu, DV 2009, 'Lithium treatment - moderate dose use study (LiTMUS) for bipolar disorder: Rationale and design', Clinical Trials, vol. 6, no. 6, pp. 637-648. https://doi.org/10.1177/1740774509347399
Nierenberg AA, Sylvia LG, Leon AC, Reilly-Harrington NA, Ketter TA, Calabrese JR et al. Lithium treatment - moderate dose use study (LiTMUS) for bipolar disorder: Rationale and design. Clinical Trials. 2009;6(6):637-648. https://doi.org/10.1177/1740774509347399
Nierenberg, Andrew A. ; Sylvia, Louisa G. ; Leon, Andrew C. ; Reilly-Harrington, Noreen A. ; Ketter, Terence A. ; Calabrese, Joseph R. ; Thase, Michael E. ; Bowden, Charles L. ; Friedman, Edward S. ; Ostacher, Michael J. ; Novak, Lena ; Iosifescu, Dan V. / Lithium treatment - moderate dose use study (LiTMUS) for bipolar disorder : Rationale and design. In: Clinical Trials. 2009 ; Vol. 6, No. 6. pp. 637-648.
@article{74cdfb34526f401aabc59deae998b630,
title = "Lithium treatment - moderate dose use study (LiTMUS) for bipolar disorder: Rationale and design",
abstract = "Background Recent data indicate that lithium use for bipolar disorder has declined over the last decade and that lithium largely has been replaced with alternate, commercially promoted medications that may or may not result in better outcomes. Purpose This article describes the rationale and study design of LiTMUS, a multisite, prospective, randomized clinical trial of outpatients with bipolar disorder. LiTMUS seeks to address whether initiating therapy at lower doses of lithium as part of optimized treatment (OPT, guideline-informed, evidence-based, and personalized pharmacotherapy) improves outcomes and decreases the need for other medication changes across 6 months of therapy. Methods LiTMUS will randomize 284 adults with bipolar disorder (Type I or II) across 6 study sites. The co-primary outcomes are overall illness severity on clinical global improvement scale for bipolar disorder and a novel measure, necessary clinical adjustments. This metric provides a composite that reflects both clinical response and tolerability. Other relevant outcomes include full symptomatic recovery, quality of life, suicidal behaviors, and moderators of suicidality. Results As of August 28th, 2009, we have consented 338 patients and randomized 281 for this study. Limitations The potential limitations of the study include an arbitrary definition of 'low, but effective' doses of lithium, lack of a placebo-controlled group, open treatment, and use of a new outcome measure (i.e., necessary clinical adjustments). Conclusion We expect that this study will inform our understanding of the effectiveness of low to moderate doses of lithium therapy for individuals with bipolar disorder.",
author = "Nierenberg, {Andrew A.} and Sylvia, {Louisa G.} and Leon, {Andrew C.} and Reilly-Harrington, {Noreen A.} and Ketter, {Terence A.} and Calabrese, {Joseph R.} and Thase, {Michael E.} and Bowden, {Charles L.} and Friedman, {Edward S.} and Ostacher, {Michael J.} and Lena Novak and Iosifescu, {Dan V.}",
year = "2009",
doi = "10.1177/1740774509347399",
language = "English (US)",
volume = "6",
pages = "637--648",
journal = "Clinical Trials",
issn = "1740-7745",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Lithium treatment - moderate dose use study (LiTMUS) for bipolar disorder

T2 - Rationale and design

AU - Nierenberg, Andrew A.

AU - Sylvia, Louisa G.

AU - Leon, Andrew C.

AU - Reilly-Harrington, Noreen A.

AU - Ketter, Terence A.

AU - Calabrese, Joseph R.

AU - Thase, Michael E.

AU - Bowden, Charles L.

AU - Friedman, Edward S.

AU - Ostacher, Michael J.

AU - Novak, Lena

AU - Iosifescu, Dan V.

PY - 2009

Y1 - 2009

N2 - Background Recent data indicate that lithium use for bipolar disorder has declined over the last decade and that lithium largely has been replaced with alternate, commercially promoted medications that may or may not result in better outcomes. Purpose This article describes the rationale and study design of LiTMUS, a multisite, prospective, randomized clinical trial of outpatients with bipolar disorder. LiTMUS seeks to address whether initiating therapy at lower doses of lithium as part of optimized treatment (OPT, guideline-informed, evidence-based, and personalized pharmacotherapy) improves outcomes and decreases the need for other medication changes across 6 months of therapy. Methods LiTMUS will randomize 284 adults with bipolar disorder (Type I or II) across 6 study sites. The co-primary outcomes are overall illness severity on clinical global improvement scale for bipolar disorder and a novel measure, necessary clinical adjustments. This metric provides a composite that reflects both clinical response and tolerability. Other relevant outcomes include full symptomatic recovery, quality of life, suicidal behaviors, and moderators of suicidality. Results As of August 28th, 2009, we have consented 338 patients and randomized 281 for this study. Limitations The potential limitations of the study include an arbitrary definition of 'low, but effective' doses of lithium, lack of a placebo-controlled group, open treatment, and use of a new outcome measure (i.e., necessary clinical adjustments). Conclusion We expect that this study will inform our understanding of the effectiveness of low to moderate doses of lithium therapy for individuals with bipolar disorder.

AB - Background Recent data indicate that lithium use for bipolar disorder has declined over the last decade and that lithium largely has been replaced with alternate, commercially promoted medications that may or may not result in better outcomes. Purpose This article describes the rationale and study design of LiTMUS, a multisite, prospective, randomized clinical trial of outpatients with bipolar disorder. LiTMUS seeks to address whether initiating therapy at lower doses of lithium as part of optimized treatment (OPT, guideline-informed, evidence-based, and personalized pharmacotherapy) improves outcomes and decreases the need for other medication changes across 6 months of therapy. Methods LiTMUS will randomize 284 adults with bipolar disorder (Type I or II) across 6 study sites. The co-primary outcomes are overall illness severity on clinical global improvement scale for bipolar disorder and a novel measure, necessary clinical adjustments. This metric provides a composite that reflects both clinical response and tolerability. Other relevant outcomes include full symptomatic recovery, quality of life, suicidal behaviors, and moderators of suicidality. Results As of August 28th, 2009, we have consented 338 patients and randomized 281 for this study. Limitations The potential limitations of the study include an arbitrary definition of 'low, but effective' doses of lithium, lack of a placebo-controlled group, open treatment, and use of a new outcome measure (i.e., necessary clinical adjustments). Conclusion We expect that this study will inform our understanding of the effectiveness of low to moderate doses of lithium therapy for individuals with bipolar disorder.

UR - http://www.scopus.com/inward/record.url?scp=77149145178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77149145178&partnerID=8YFLogxK

U2 - 10.1177/1740774509347399

DO - 10.1177/1740774509347399

M3 - Article

VL - 6

SP - 637

EP - 648

JO - Clinical Trials

JF - Clinical Trials

SN - 1740-7745

IS - 6

ER -